News - Page 3 of 10

General 9. July 2024

OCCIDENT Launches Project Study Opportunity for TUM Students

We provide an exceptional opportunity for students at the Technical University of Munich to gain hands-on experience in venture capital while earning credits towards their Master's programs.

Life Sciences 27. June 2024

Tubulis Receives FDA Fast Track Designation

Tubulis' TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.

Life Sciences 20. June 2024

Tubulis Doses First Patient in Phase I/IIa Trial for TUB-040

UB-040 targets an overexpressed antigen in ovarian and lung adenocarcinoma. The trial will enroll up to 140 patients across the US, UK, and Europe.

Team 7. June 2024

OCCIDENT Insights: We improve communication

The OCCIDENT Team regularly improves its soft skills to enhance collaboration both internally and externally. In addition to our professional skills, we attach great importance to teamwork.

Life Sciences 14. May 2024

Avelo collaborates with global health leaders in project “BreathForDiagnosis”

The €3 million research project is funded by the European Commission under "Horizon Europe", and co-funded by the Swiss State Secretariat for Education, Research and Innovation (SERI).

About 18. April 2024

Moments to Remember: 4th OCCIDENT Pitch Event in Munich

Thank you for inspiring pitches, engaging conversations, and meaningful connections

About 9. April 2024

New OCCIDENT Website

Having sharpened our investor profile and revised our communication, we get to the point: OCCIDENT – The Science Investor.

Life Sciences 25. March 2024

Follow-on investment in hemotune

Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.

Life Sciences 20. March 2024

Resistell is publishing in Nature!

A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.